The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 (‘Iressa’ ) is not related to the expression of EGFR or HER-2 or to K-ras gene status
Authors:
- Taku NakagawaTNTaku Nakagawa
- Hideki EndoHEHideki Endo
- Tetsuya MitsudomiTMTetsuya Mitsudomi
- Akira MasudaAMAkira Masuda
- Yasushi YatabeYYYasushi Yatabe
- Takahiko SugiuraTSTakahiko Sugiura
- Takashi TakahashiTTTakashi Takahashi
- Toyoaki HidaTHToyoaki Hida
- 1 October 2003
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 42 (1) , 35-41
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Health and Welfare
- Daiko Foundation
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 14 references indexed in Scilit:
- Tyrosine Kinase Inhibitors Targeted to the Epidermal Growth Factor Receptor SubfamilyDrugs, 2000
- Anticancer drug targets: growth factors and growth factor signalingJournal of Clinical Investigation, 2000
- The Epidermal Growth Factor Receptor and Its Inhibition in Cancer TherapyPharmacology & Therapeutics, 1999
- Protein modules and signalling networksNature, 1995
- Epidermal growth factor.Journal of Biological Chemistry, 1990
- Identification of a novel autophosphorylation site (P4) on the epidermal growth factor receptorBiochemical Journal, 1989
- Over‐expression of the EGF receptor is a hallmark of squamous cell carcinomasThe Journal of Pathology, 1986
- EPIDERMAL-GROWTH-FACTOR RECEPTORS IN HUMAN BLADDER CANCER: COMPARISON OF INVASIVE AND SUPERFICIAL TUMOURSThe Lancet, 1985
- EPIDERMAL-GROWTH-FACTOR RECEPTORS AND OESTROGEN RECEPTORS IN HUMAN BREAST CANCERThe Lancet, 1985
- Autophosphorylation sites on the epidermal growth factor receptorNature, 1984